| 1 |
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith et al. · The Lancet
|
2007 |
1,521 |
| 2 |
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
José Baselga et al. · The Lancet
Open access |
16 Jan 2012 |
1,324 |
| 3 |
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
David Cameron, Martine J Piccart, Richard D. Gelber et al. · The Lancet
Open access |
16 Feb 2017 |
1,052 |
| 4 |
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab
Roberto Salgado, Carsten Denkert, Christine E. Campbell et al. · JAMA Oncology
Open access |
30 Apr 2015 |
621 |
| 5 |
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
Luca Gianni et al. · The Lancet Oncology
|
26 Feb 2011 |
614 |
| 6 |
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
Aron Goldhirsch et al. · The Lancet
|
17 Jul 2013 |
504 |
| 7 |
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Charles E. Geyer et al. · Annals of Oncology
Open access609 authors |
10 Oct 2022 |
477 |
| 8 |
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
Evandro de Azambuja et al. · The Lancet Oncology
|
14 Aug 2014 |
461 |
| 9 |
Corticosteroids for Bell's palsy (idiopathic facial paralysis)
Vishnu B. Madhok, Ildikó Gágyor, Fergus Daly et al. · Cochrane Database of Systematic Reviews
Open access |
18 Jul 2016 |
390 |
| 10 |
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up
Martine J Piccart et al. · Journal of Clinical Oncology
Open access |
4 Feb 2021 |
374 |
| 11 |
Population-Based Colonoscopy Screening for Colorectal Cancer
Michael Bretthauer et al. · JAMA Internal Medicine
Open access |
23 May 2016 |
329 |
| 12 |
Endoscopist deskilling risk after exposure to artificial intelligence in colonoscopy: a multicentre, observational study
Krzysztof Budzyń et al. · The Lancet. Gastroenterology & hepatology
|
12 Aug 2025 |
265 |
| 13 |
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
S. Loibl, Ian J. Majewski, Valentina Guarneri et al. · Annals of Oncology
Open access |
13 May 2016 |
236 |
| 14 |
CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)
Bernhard C. Pestalozzi, Eileen McCormick Holmes, Evandro de Azambuja et al. · The Lancet Oncology
|
12 Feb 2013 |
213 |
| 15 |
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial
Michael Untch et al. · Annals of Oncology
Open access |
23 Feb 2008 |
198 |
| 16 |
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative
Philippe Georges Aftimos et al. · Cancer Discovery
Open access |
28 Jun 2021 |
187 |
| 17 |
Effectiveness of Acupuncture for Low Back Pain
Jing Yuan, Nithima Purepong, Daniel Paul Kerr et al. · Spine
|
28 Oct 2008 |
178 |
| 18 |
Antiviral treatment for Bell's palsy (idiopathic facial paralysis)
Ildikó Gágyor, Vishnu B. Madhok, Fergus Daly et al. · Cochrane Database of Systematic Reviews
Open access |
9 Nov 2015 |
176 |
| 19 |
18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO
Géraldine Gebhart, Cristina Gámez, Eileen McCormick Holmes et al. · Journal of Nuclear Medicine
Open access |
3 Oct 2013 |
162 |
| 20 |
Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Françoise Rothé et al. · Clinical Cancer Research
Open access |
12 Mar 2019 |
130 |
| 21 |
Antibodies to TR2 (Herpesvirus Entry Mediator), a New Member of the TNF Receptor Superfamily, Block T Cell Proliferation, Expression of Activation Markers, and Production of Cytokines
Jeremy Harrop, Manjula P Reddy, Kimberly Dede et al. · The Journal of Immunology
Open access |
Aug 1998 |
127 |
| 22 |
The impact of a bodyweight and physical activity intervention (BeWEL) initiated through a national colorectal cancer screening programme: randomised controlled trial
Annie S. Anderson, Angela Mary Craigie, Stephen Caswell et al. · BMJ
Open access |
7 Mar 2014 |
119 |
| 23 |
Rationale and design of the European Polyp Surveillance (EPoS) trials
Rodrigo Jover et al. · Endoscopy
Open access |
4 Apr 2016 |
113 |
| 24 |
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients
Matteo Lambertini et al. · JNCI Journal of the National Cancer Institute
Open access |
18 Apr 2018 |
105 |
| 25 |
Online support groups for women with breast cancer
Eilís McCaughan, Kader Parahoo, Irene Hueter et al. · Cochrane Database of Systematic Reviews
Open access |
10 Mar 2017 |
98 |
| 26 |
Pedometer-driven Walking for Chronic Low Back Pain
Suzanne McDonough, Mark A. Tully, Adele Boyd et al. · Clinical Journal of Pain
Open access |
27 Feb 2013 |
95 |
| 27 |
Survival outcomes of the NeoALTTO study (BIG 1–06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer
Jens Huober et al. · European Journal of Cancer
Open access |
Aug 2019 |
90 |
| 28 |
A key to the Lichen-Forming, Parasitic, Parasymbiotic and Saprophytic Fungi Occurring on Lichens in the British Isles
David L. Hawksworth · The Lichenologist
|
Feb 1983 |
90 |
| 29 |
Cross-trimester repeated measures testing for Down’s syndrome screening: an assessment
Donald S. Wright, Ian Bradbury, Fergal Desmond Malone et al. · Health Technology Assessment
Open access |
Jul 2010 |
90 |
| 30 |
Valuation framework for large scale electricity storage in a case with wind curtailment
Rodica Loisel, Arnaud Mercier, Christoph Gatzen et al. · Energy Policy
|
22 Aug 2010 |
88 |
| 31 |
Declining Business Dynamism in the U.S. High-Technology Sector
John Haltiwanger, Ian Hathaway, Javier Miranda · SSRN Electronic Journal
PreprintOpen access |
2014 |
84 |
| 32 |
Lung Clearance Index is a Repeatable and Sensitive Indicator of Radiological Changes in Bronchiectasis
Stephen Rowan, Judy Martina Bradley, Ian Bradbury et al. · American Journal of Respiratory and Critical Care Medicine
|
Mar 2014 |
76 |
| 33 |
Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01)
Hatem A. Azim, Otto Metzger, Evandro de Azambuja et al. · Breast Cancer Research and Treatment
|
25 Feb 2012 |
75 |
| 34 |
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2–positive early breast cancer: Analysis from the NeoALTTO (BIG 1‐06) and ALTTO (BIG 2‐06) trials
Matteo Lambertini, Samuel Martel, Christine E. Campbell et al. · Cancer
Open access |
18 Oct 2018 |
73 |
| 35 |
Enhancement of artemisinin concentration and yield in response to optimization of nitrogen and potassium supply to Artemisia annua
Michael J. Davies, Christopher John Atkinson, Corrinne Burns et al. · Annals of Botany
Open access |
30 May 2009 |
71 |
| 36 |
A pooled analysis of the cardiac events in the trastuzumab adjuvant trials
Evandro de Azambuja, Noam Falbel Ponde, Marion Jennifer Procter et al. · Breast Cancer Research and Treatment
Open access |
11 Oct 2019 |
70 |
| 37 |
Education of healthcare professionals for preventing pressure ulcers
Alison P Porter-Armstrong, Zena Moore, Ian Bradbury et al. · Cochrane Database of Systematic Reviews
Open access |
25 May 2018 |
69 |
| 38 |
Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study
Rina Hui et al. · Clinical Cancer Research
Open access |
16 Oct 2019 |
64 |
| 39 |
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)
Noam Falbel Ponde et al. · Breast Cancer Research and Treatment
Open access |
26 Dec 2017 |
62 |
| 40 |
Exercise and Auricular Acupuncture for Chronic Low-back Pain
Ruth Fiona Hunter, Suzanne McDonough, Ian Bradbury et al. · Clinical Journal of Pain
|
13 Jul 2011 |
62 |
| 41 |
A few things transport regulators should know about risk and the cost of capital
Ian Alexander, Antonio Estache, Adele Oliveri · Utilities Policy
|
Mar 2000 |
61 |
| 42 |
Tech Starts: High-Technology Business Formation and Job Creation in the United States
Ian Hathaway · SSRN Electronic Journal
PreprintOpen access |
2013 |
60 |
| 43 |
Ex post appraisal: What lessons can be learnt from EU cohesion funded transport projects?
Charlotte M Kelly, James J. Laird, Stefano Costantini et al. · Transport Policy
|
14 Nov 2014 |
57 |
| 44 |
Development of an X-ray computed tomography (CT) system with sparse sources: application to three-phase pipe flow visualization
Bin Hu, Colin J. Stewart, Colin P. Hale et al. · Experiments in Fluids
|
24 Jun 2005 |
54 |
| 45 |
The gut metabolite indole-3-propionic acid activates ERK1 to restore social function and hippocampal inhibitory synaptic transmission in a 16p11.2 microdeletion mouse model
Jian Wei Jiang, Dilong Wang, Youheng Jiang et al. · Microbiome
Open access |
28 Mar 2024 |
52 |
| 46 |
VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up
Sibylle Loibl, Jacek Jassem, Amir Sonnenblick et al. · Annals of Oncology
Open access |
15 Jul 2022 |
52 |
| 47 |
Mobile Termination: What is the “Right” Charge?*
Tommaso Valletti, George Houpis · Journal of Regulatory Economics
|
4 Oct 2005 |
51 |
| 48 |
RaVÆn: unsupervised change detection of extreme events using ML on-board satellites
Vít Růžička, Anna Vaughan, Daniele De Martini et al. · Scientific Reports
Open access |
8 Oct 2022 |
50 |
| 49 |
Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial
Carmen Criscitiello, Hatem A. Azim, Dominique Agbor‐Tarh et al. · Annals of Oncology
Open access |
9 Apr 2013 |
50 |
| 50 |
Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer
Michail Ignatiadis et al. · JAMA
Open access |
30 Jan 2025 |
49 |